Journal for Immunotherapy of Cancer 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
AbstractThe therapeutic landscape in metastatic melanoma has changed dramatically in the last decade, with the success of immune checkpoint inhibitors resulting in durable responses for a large number of patients. For patients withBRAF mutations, combinations of BRAF and MEK inhibitors demonstrated response rates and benefit comparable to those from immune checkpoint inhibitors, providing the rationale for sequential treatment with targeted and immunotherapies and raising the question of optimal treatment sequencing.Biomarkers for the selection of anti-PD-1 therapy inBRAF wild type (BRAF WT) and inBRAF mutated (BRAF MUT) p...
Source: Journal for Immunotherapy of Cancer - March 28, 2019 Category: Cancer & Oncology Source Type: research
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
AbstractQuantitative lymphocyte alterations are frequent in patients with cancer, and strongly impact prognosis and survival. The development of cancers in immunosuppressed patients has demonstrated the contribution of different T cell populations, including CD4+ cells, in the control of cancer occurrence.Whereas absolute numbers of neutrophils, platelets and red blood cells are routinely monitored in clinic following treatments, because of possible short-term complications, absolute lymphocyte counts (ALC), their subpopulations or diversity (phenotype, TCR) are rarely analyzed and never used to choose therapy or as progno...
Source: Journal for Immunotherapy of Cancer - March 27, 2019 Category: Cancer & Oncology Source Type: research
Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification
ConclusionsIn this hypothesis-generating study, deepening our understanding of immune-checkpoint biology, comprehensive protein-protein interaction and pathway mapping revealed that redundant immune-checkpoint interactors associate with positive outcomes, providing new avenues for the deciphering of molecular mechanisms behind effects of immunotherapeutic agents targeting immune-checkpoints analyzed. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 27, 2019 Category: Cancer & Oncology Source Type: research
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
ConclusionsThese findings show that targeted NGS, a readily available clinical diagnostic test, can be used to identify patients with SCLC who are most likely to benefit from treatment with immune checkpoint inhibitors. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 27, 2019 Category: Cancer & Oncology Source Type: research
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM SM registry
ConclusionsAmong mRCC patients treated with HD IL-2, all risk groups have median and 2-year survival consistent with recent reports of checkpoint or targeted therapies for mRCC. Favorable and intermediate risk (by IMDC) patients treated with HD IL-2 have longer OS compared with poor risk patients, with most durable OS observed in favorable risk patients. Favorable risk patients treated with HD IL-2 alone have a 2-year OS of 74%. These data continue to support a recommendation for HD IL-2 for patients with mRCC who meet eligibility criteria.Trial registrationPROCLAIM,NCT01415167 was registered with ClinicalTrials.gov on Aug...
Source: Journal for Immunotherapy of Cancer - March 26, 2019 Category: Cancer & Oncology Source Type: research
Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series
ConclusionsThis report suggests that systemic immunotherapy with or without topical interferon is effective in treatment of malignant melanoma of the conjunctiva. Therefore, it can be considered for patients with advanced local conjunctival melanoma, those who refuse orbital exenteration surgery and those with systemic metastasis. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 24, 2019 Category: Cancer & Oncology Source Type: research
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
ConclusionsWe provide novel insight into the mechanism of action of N-803 plus anti-PD-L1 combination and offer preclinical proof of concept supporting clinical use of N-803 in combination with checkpoint inhibitors, including for patients non- and/or minimally responsive to either monotherapy. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 20, 2019 Category: Cancer & Oncology Source Type: research
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
ConclusionsWhen combined with ipilimumab, epacadostat ≤50 mg BID demonstrated clinical and pharmacologic activity and was generally well tolerated in patients with advanced melanoma.Trial registrationClinicalTrials.gov identifier,NCT01604889. Registration date, May 9, 2012, retrospectively registered. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 19, 2019 Category: Cancer & Oncology Source Type: research
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
AbstractConsolidation therapies for children with intermediate- or high-risk acute myeloid leukemia (AML) are urgently needed to achieve higher cure rates while limiting therapy-related toxicities. We determined if adoptive transfer of natural killer (NK) cells from haploidentical killer immunoglobulin –like receptor (KIR)–human leukocyte antigen (HLA)-mismatched donors may prolong event-free survival in children with intermediate-risk AML who were in first complete remission after chemotherapy. Patients received cyclophosphamide (Day − 7), fludarabine (Days − 6 through − 2), and s ubcutaneous interleukin-2...
Source: Journal for Immunotherapy of Cancer - March 19, 2019 Category: Cancer & Oncology Source Type: research
Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
ConclusionsAltogether, these results suggest that IL-1 α in combination with cetuximab can induce a T cell-dependent anti-tumor immune response and may represent a novel immunotherapeutic strategy for EGFR-positive HNSCCs. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 18, 2019 Category: Cancer & Oncology Source Type: research
HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
ConclusionsCompared with PD-L1, HHLA2 is more prevalent and possesses more explicit prognostic significance, which confer the rationale for HHLA2 as a potential immunotherapeutic target next to PD-L1 for ICC patients. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 17, 2019 Category: Cancer & Oncology Source Type: research
Merger of dynamic two-photon and phosphorescence lifetime microscopy reveals dependence of lymphocyte motility on oxygen in solid and hematological tumors
ConclusionsThis study demonstrates a versatile and highly contextual FaST-PLIM method for phosphorescence lifetime-based oxygen imaging in living animal tumor immunology models. The initial results of this method application to ALL and solid lung tumor models highlight the importance of oxygen supply for the maintenance of intratumoral T cell migration, define a 5 mmHg local oxygen concentration threshold for TIL motility, and demonstrate efficacy of supplementary oxygen breathing in TIL motility enhancement coincident with reduction of tumor hypoxia. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 17, 2019 Category: Cancer & Oncology Source Type: research
Correction to: A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity
. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 14, 2019 Category: Cancer & Oncology Source Type: research
Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
ConclusionsH-Zt/g4-MMAE is superior in eradication of pancreatic cancer xenografts with favorable pharmacokinetic profiles and manageable toxicological activities. These findings warrant the transition of H-Zt/g4-MMAE into clinical trials in the future. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 13, 2019 Category: Cancer & Oncology Source Type: research
Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment
ConclusionsAltogether, we show that tumor spheroids represent a relevant tool to study tumor-lymphocyte interactions on human tissues and revealed the antitumor potential of immunomodulatory antibodies targeting MICA/B and NKG2A. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 13, 2019 Category: Cancer & Oncology Source Type: research
